首页> 外文期刊>International Journal of Pharmaceutics >The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats.
【24h】

The preparation of silybin-phospholipid complex and the study on its pharmacokinetics in rats.

机译:水飞蓟宾-磷脂复合物的制备及其在大鼠体内的药代动力学研究。

获取原文
获取原文并翻译 | 示例
           

摘要

The aim of the present study was to find a way of prepare silybin-phospholipid complex to make oral bioavailability of silybin increase and to study its physicochemical properties and to compare the pharmacokinetic characteristics and bioavailability after oral administration of silybin-phospholipid complex and silybin-N-methylglucamine in rats. Using ethanol as a reaction medium, silybin and phospholipids were resolved into the medium, after the organic solvent was removed under vacuum condition, silybin-phospholipid complex was formed. The new complex's physicochemical properties including scanning electron microscopy (SEM), transmission electron microscopy (TEM), differential scanning calorimetry (DSC), solubility, dissolution, etc., were tested. The concentrations of silybin after oral administration of silybin-phospholipid complex and silybin-N-methylglucamine at different time in rats were determined by RP-HPLC. The pharmacokinetic parameters were computed by software program 3p97. Our data showed that silybin and phospholipids in the silybin-phospholipid complex were combined by non-covalent-bond, not forming a new compound and the solubility of silybin-phospholipid complex in water and in n-octanol was effectively enhanced. We found that mean plasma concentration-time curve of silybin after oral administration of silybin-phospholipid complex and silybin-N-methylglucamine in rats was both in accordance with open single-compartment model with first-order absorption. Pharmacokinetic parameters of silybin in rats were Tmax 10 and 5 min; Cmax 126.72 and 104.29 ng ml(-1); AUC(0-infinity) 1020.33 and 235.81 ng ml(-1)h, respectively. The bioavailability of silybin in rats was increased remarkably after oral administration of silybin-phospholipid complex comparing to silybin-N-methylglucamine. This was mainly due to an impressive improvement of the lipophilic property of silybin-phospholipid complex and improvement of the biological effect of silybin.
机译:本研究的目的是找到制备水飞蓟宾-磷脂复合物的方法,以提高水飞蓟宾的口服生物利用度,研究其理化性质,比较水飞蓟宾-磷脂复合物和水飞蓟宾-N口服后的药代动力学特性和生物利用度。 -甲基葡萄糖胺在大鼠中。用乙醇作为反应介质,将水飞蓟宾和磷脂溶解在该介质中,在真空条件下除去有机溶剂后,形成水飞蓟宾-磷脂复合物。测试了新复合物的物理化学性质,包括扫描电子显微镜(SEM),透射电子显微镜(TEM),差示扫描量热法(DSC),溶解度,溶解度等。通过RP-HPLC测定大鼠在不同时间口服水飞蓟宾-磷脂复合物和水飞蓟宾-N-甲基葡糖胺后水飞蓟宾的浓度。通过软件程序3p97计算药代动力学参数。我们的数据表明,水飞蓟宾-磷脂复合物中的水飞蓟宾和磷脂通过非共价键结合在一起,没有形成新的化合物,水飞蓟宾-磷脂复合物在水中和在正辛醇中的溶解度得到有效提高。我们发现口服水飞蓟宾-磷脂复合物和水飞蓟宾-N-甲基葡糖胺后,水飞蓟宾的平均血浆浓度-时间曲线均符合开放式一室吸收模型。水飞蓟宾在大鼠体内的药代动力学参数为Tmax 10和5 min; Cmax 126.72和104.29 ng ml(-1); AUC(0-无穷大)1020.33和235.81 ng ml(-1)h。与水飞蓟宾-N-甲基葡糖胺相比,水飞蓟宾-磷脂复合物口服后大鼠水飞蓟宾的生物利用度显着增加。这主要归因于水飞蓟宾-磷脂复合物的亲脂性的显着改善和水飞蓟宾的生物学作用的改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号